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Abstract
Background: Evidence from clinical trial populations suggests low-dose aspirin reduces the risk of colorectal cancer
(CRC). Part of this reduction in risk might be due to protection against metastatic disease.
Methods: We investigated the risk of CRC among new-users of low-dose aspirin (75–300 mg), including risk by stage
at diagnosis. Using The Health Improvement Network, we conducted a cohort study with nested case–control analysis.
Two cohorts (N = 170,336 each) aged 40–89 years from 2000 to 2009 and free of cancer were identified: i) new-users of
low-dose aspirin, ii) non-users of low-dose aspirin, at start of follow-up, matched by age, sex and previous primary care
practitioner visits. Patients were followed for up to 12 years to identify incident CRC. 10,000 frequency-matched controls
were selected by incidence density sampling where the odds ratio is an unbiased estimator of the incidence rate ratio
(RR). RRs with 95% confidence intervals were calculated. Low-dose aspirin use was classified ‘as-treated’ independent
from baseline exposure status to account for changes in exposure during follow-up.
Results: Current users of low-dose aspirin (use on the index date or in the previous 90 days) had a significantly reduced
risk of CRC, RR 0.66 (95% CI 0.60–0.74). The reduction in risk was apparent across all age groups, and was unrelated to
dose, indication, gender, CRC location or case-fatality status. Reduced risks occurred throughout treatment duration and
with all low-dose aspirin doses. RRs by aspirin indication were 0.71 (0·63–0·79) and 0.60 (0.53–0.68) for primary and
secondary cardiovascular protection, respectively. Among cases with staging information (n = 1421), RRs for current use
of low-dose aspirin were 0.94 (0.66–1.33) for Dukes Stage A CRC, 0.54 (0.42–0.68) for Dukes B, 0.71 (0.56–0.91) for Dukes
C, and 0.60 (0.48–0.74) for Dukes D. After 5 years’ therapy, the RR for Dukes Stage A CRC was 0.53 (0.24–1.19).
Conclusions: Patients starting low-dose aspirin therapy have a reduced risk of Stages B–D CRC, suggesting a role for
low-dose aspirin in the progression of established CRC; a substantial reduction in the risk of Dukes A CRC may occur
after 5 years’ therapy.
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Background
Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer worldwide, with more than 1.3 million
new cases reported in 2012 [1]. Long-term (up to
20 years) follow-up of cardiovascular trials have demon-
strated, in post hoc analyses, that patients randomized
to daily low-dose aspirin (75–300 mg) have a reduced
risk of CRC incidence and mortality after a delay of sev-
eral years [2]. The hypothesis that aspirin has a chemo-
preventive effect early in the adenoma sequence in CRC
development is consistent with this latency period, and
is supported by findings from randomized controlled tri-
als (RCTs) showing daily low-dose aspirin (81–325 mg)
reduces colorectal adenoma recurrence in average/high-
risk populations [3].
In early cardiovascular trials, the protective effect of
low-dose aspirin against CRC was greatest in patients
with longer scheduled duration of trial treatment [2].
However, analyses were limited based on unknown as-
pirin exposure during the post-trial follow-up period,
and inability to adjust for confounders. Patients who dis-
continued aspirin in the intervention arm or started
treatment in the placebo arm after the randomized
phase would have been analyzed according to exposure
status at randomization, thus the protective effect of as-
pirin could have been mainly due to chronic aspirin ex-
posure over the relatively short in-trial period. Recent
analyses of in-trial data show that aspirin substantially
reduces metastatic CRC at initial diagnosis [4], which
cannot be accounted for by an effect early in the aden-
oma–carcinoma sequence. Observational data suggest
aspirin may reduce the risk of metastatic breast [5] and
prostate [6] cancer at initial presentation, and reduced
mortality has been reported for CRC [7] and breast can-
cer [8] with aspirin use following diagnosis. Aspirin may
therefore have an inhibitory effect on the growth and
spread of tumours as well as on their initial develop-
ment, and this effect could be explored further in real-
world patients by the evaluation of low-dose aspirin on
the risk of different stage CRC in clinical practice.
Methods
Using a UK primary care database of electronic medical
records (EMRs), we carried out a cohort study with
nested case–control analysis to evaluate the association
between use of low-dose aspirin and risk of incident
CRC, both overall and by aspirin dose, duration of use
and indication. We also aimed to assess the overall as-
sociation between low-dose aspirin and CRC risk by
CRC stage at diagnosis, site and case-fatality status, as
well as among patients with or without previous bowel
investigations (colonoscopy/sigmoidoscopy). We hy-
pothesized that the strength of association between
low-dose aspirin and CRC would vary by Dukes stage
at diagnosis. An independent scientific review commit-
tee for THIN (reference number 12-044 V) approved
the study protocol.
Data source
We used The Health Improvement Network (THIN)
database, which contains computerized primary care
data for ~6% of the UK population [9] and is demo-
graphically representative of the UK population as a
whole [10]. Clinical data are entered as part of routine
patient care using Read codes [11], although further
details can be added as free text, and prescriptions are
automatically recorded upon issue. Further details about
the database are described elsewhere. [12, 13] At the
time the study was carried out, approximately one fifth
of practices contributing to THIN were linked to
Hospital Episode Statistics (HES) [14], thus information
from secondary care could be obtained for individuals in
these practices.
Source population and identification of the two study cohorts
The source population included individuals in THIN
aged between 40 and 84 years from 1 January 2000 to
31 December 2009 who met the following data quality
and completeness standards: at least 2 years of registra-
tion with the general practice, a minimum of 1 year
since the beginning of computerized prescription his-
tory, and a minimum of one health encounter in the
previous 3 years. Individuals with a prescription for
low-dose aspirin or a diagnosis of cancer any time be-
fore the study entry were excluded. From within the
source population we identified all new-users of low-
dose aspirin (N = 170,336) and matched each one to an
individual still free of low-dose aspirin on that day (1:1
matching). Matching criteria were age, sex and PCP
visits in the previous year (as a proxy for general
health/comorbidity and as an attempt to control for dif-
ferences between users and non-users of aspirin at the
start of follow-up that are otherwise difficult to con-
trol). Details on the identification of the two cohorts
can be found in Additional file 1). The matching date
was set as the start date (start of follow-up) for the
identification of incident CRC cases.
CRC case identification and validation
Both study cohorts were followed-up from the start date
until a Read code suggestive of CRC (see Additional file 2),
a recorded diagnosis of another cancer, age 90 years,
death, or end of the study period (31 December 2011;
Fig. 1), whichever came first. The maximum duration of
follow-up was therefore 12 years. A total of 3805 individ-
uals had a CRC Read code during follow-up, and had their
EMRs (with free text comments) manually reviewed while
masked to aspirin exposure [13]. Patients were deemed
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incident cases unless there was evidence from the patient
record suggesting otherwise; for example, a prevalent case,
an uncertain diagnosis following biopsy results, or pres-
ence of a second primary cancer either concurrently or
previously. Information relating to the CRC diagnosis was
extracted, including (where available) details on CRC type
(colon or rectum), stage (available in the free-text com-
ments only), surgery related to the event, adjuvant therapy
treatment, and procedures involved in the diagnosis (e.g.
colonoscopy, sigmoidoscopy). The index date was the
earliest of the following: the date of the first CRC-related
symptom, the date of screening/diagnostic procedure, or
the date of surgery. In cases where the index date was un-
clear (for instance, when patients presented several times
to their PCP with non-specific symptoms), an external
gastroenterologist was consulted to ascertain the most
likely index date. In the majority of CRC cases (83%), the
index date was backdated from the date of the recorded
CRC diagnosis; the mean number of backdated days was
56.6 and the median was 36.0. Two external data sources
were used to validate the incident CRC cases ascertained
in THIN following the manual review process: 1) ques-
tionnaires sent to PCPs (for a random sample of 100
cases), and 2) HES data for individuals in linked practices.
Findings from the validation process have been published
previously [13].
Control selection
Ten thousand controls were randomly sampled and
frequency-matched to CRC cases by age, sex, and year
of the index date. Incidence density sampling was used
Fig. 1 Flowchart depicting the nested case–control study design. CRC, colorectal cancer; PCP, primary care practitioner
García Rodríguez et al. BMC Cancer  (2017) 17:637 Page 3 of 11
where the likelihood of being selected as a control was
proportional to the individual’s person-time at risk. All
eligibility criteria applied to cases were also applied to
controls.
Statistical analysis
Nested case–control analysis was carried out using
cases and controls arising from the two cohorts to
evaluate the association between low-dose aspirin use
and other potential risk factors (see Additional file 1
for further details), and CRC. Odds ratios (ORs) with
95% confidence intervals (CIs) were calculated using
unconditional logistic regression. By using incidence
density sampling, the OR is an unbiased estimator of
the incidence rate ratio (RR) [15]. Drug treatment
was categorised as follows: current use, use on the
index date or in the previous 90 days; recent/past use,
use ≥91 days before the index date; and non-use,
when there was no prescription any time prior to the
index date. Using these definitions of actual aspirin
use in relation to the index date, rather than aspirin
exposure determined solely at the start of follow-up,
enabled us to account for changes in individuals’ low-
dose aspirin exposure over time, which could happen
with a long follow-up period such as in this study.
Any member of either study cohort could have used
low-dose aspirin at or before the index date, not just
those designated to the low-dose aspirin cohort at the
start of follow-up. For example, a member of the
non-user cohort may have initiated use of the drug
during follow-up and vice versa). Although low-dose
aspirin can be obtained over-the-counter (OTC) in
the UK, access to healthcare is straightforward and
prescriptions are free for individuals aged ≥60 years,
which is the age range of the patient population that
most commonly uses low-dose aspirin – a factor
likely to encourage prescription. Furthermore, our
previous validation study in THIN showed the impact
of potential misclassification of low-dose aspirin in
the database owing to unrecorded OTC aspirin use
would be minimal [16]. In addition, as part of an-
other study using the Clinical Practice Research Data-
link (CPRD; a similar database to THIN), nearly all
chronic low-dose aspirin use was via prescription
[17]. Duration of therapy was calculated for current
low-dose aspirin users by totalling the individual
lengths of all consecutive prescriptions with treatment
gaps greater than 90 days considered genuine breaks
in therapy. Stratified and sub-group analyses were
performed and interaction terms were used to test for
potential effect modification by age, sex and CRC
stage at diagnosis. Sensitivity analyses were carried
out restricting to CRC cases with known CRC stage.
Analyses were undertaken with STATA version 12.0.
Results
Descriptive findings
Characteristics of both study cohorts at the start of
follow-up are presented in Table 1. New users of low-
dose aspirin at the start of follow-up had a higher
frequency of comorbidities, smokers, and overweight
individuals. Similar proportions of patients between the
two cohorts had a previous record of a colonoscopy,
sigmoidoscopy or a gastrointestinal polyp. Over a mean
follow-up of 5.32 years (95% CI: 5.31–5.33), 3303 inci-
dent cases of CRC were identified after manual review of
patient’s EMRs. Clinical features of the malignancies are
shown in Additional file 3. Among those with recorded
staging (N = 1421), about one third (34.9%) were Dukes
Stage D, and a quarter (26.0%) were Dukes Stage C. The
mean age of cases was 68 years and 59% were male. Time
to CRC occurrence was similar across Dukes Stages (see
Additional file 4). Approximately 80% (n = 2433) of CRC
cases were still alive at 1-year post index date (non-fatal
cases), of which 48% were male. Overall, 54% of cases
were still alive at 5 years; 87% of Dukes Stage A cases, and
78%, 57%, 9% and 57% of Dukes Stages B, C, D and
unknown stage cases, respectively. Cases with or without
recorded staging were similar in terms of demographics,
recorded symptoms and diagnostic investigations (see
Additional files 5 and 6). Greater use of health care
contacts (hospitalizations, referrals and PCP visits) in the
year prior to the index date, former smoking and higher
alcohol consumption were significant predictors of CRC,
while none of the comorbidities evaluated showed a clear
association with CRC (Table 2).
Low-dose aspirin use and risk of CRC
Associations between use of low-dose aspirin and risk of
CRC are presented in Table 3. Current low-dose aspirin
users had a 34% statistically significant decreased risk of
CRC, RR 0.66 (95% CI: 0.60–0.73). A decreased risk of
CRC was observed with all aspirin doses evaluated – 75,
150 or 300 mg/day – although the latter dose was not
statistically significant, with no dose–response relation-
ship observed within this range. Among cases and con-
trols, approximately two-thirds of all current low-dose
aspirin use was of at least 1-year duration. A reduction
in CRC risk was seen throughout treatment duration,
with a constant 40% reduction after the first year. Asso-
ciations between current use of low-dose aspirin and
CRC by subpopulation (age, gender, low-dose aspirin in-
dication, prior gastrointestinal antecedents and prior
colonoscopy/sigmoidoscopy/gastrointestinal adenoma)
as well as by features of the cancer (Dukes’s stage, type
[colon or rectum], location and fatality) are shown in
Fig. 2). Low-dose aspirin was associated with a 40% sta-
tistically significant reduced risk of CRC when used for
secondary CVD prevention and approximately a 30%
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reduced risk when used for primary CVD prevention
(Fig. 2). A 30–40% significant protective effect was
seen for both fatal and non-fatal cases, for colon or
rectal CRC, for both men and women, and across all
age groups. Age didn’t modify the protective effect of
low-dose aspirin (p for interaction = 0.27), and no dif-
ferences were seen between men and women (p for
interaction = 0.24). The reduced risk of CRC with low-
dose aspirin was also observed among patients with or
without GI antecedents, as well as among those with
or without previous colonoscopy/sigmoidoscopy/
gastrointestinal adenoma.
Significantly decreased risks of CRC were observed for
Dukes Stages B to D; RR 0.54 (95% CI 0.42–0.68) for
Dukes Stage B, RR 0.71 (95% CI 0.56–0.91) for Dukes
Stage C, and RR 0.60 (95% CI: 0.48–0.74) for Dukes
Stage D (Fig. 2), with the reduction in risk seen through-
out treatment duration (see Additional file 7). For cases
with unknown cancer stage, the RR was 0.68 (95% CI:
0.60–0.78). Colorectal cancer stage at diagnosis was
found to significant modify the protective effect of low-
dose aspirin (p for interaction = 0.03). The RR for Dukes
Stage A was 0.94 (95% CI: 0.66–1.33), with no reduction
in risk observed with less than 1 year of treatment, but
with the suggestion of a substantial risk reduction after
5 years’ therapy, RR 0.53 (95% CI: 0.24–1.19; only seven
Dukes Stage A CRC cases had at least 5 years’ low-dose
aspirin exposure). Results restricting our analysis to only
CRC cases with recorded stage are shown in Additional
file 8. In the 1-year lag-time analysis (using all cases





apirin at start of follow-up cohort
N = 169,992a
n (%)
New users of low-dose
aspirin at start of follow-up cohort
N = 170,225a
n (%)
Hypertension 80,269 (23.6) 55,228 (32.5) 25,041 (14.7)
Diabetes 46,994 (13.8) 12,365 (7.3) 34,629 (20.3)
COPD 16,677 (4.9) 7891 (4.6) 8786 (5.2)
IBD 4073 (1.2) 2061 (1.2) 2012 (1.2)
Depression 69,241 (20.4) 31,654 (18.6) 37,587 (22.1)
GI conditions 71,961 (21.2) 33,161 (19.5) 38,800 (22.8)
Record of prior colonoscopy,
sigmoidoscopy or GI polyp
30,150 (8.9) 14,262 (8.4) 15,888 (9.3)
Smoking
Non-smoker 150,723 (44.3) 79,726 (46.9) 70,997 (41.7)
Current smoker 67,598 (19.9) 31,157 (18.3) 36,441 (21.4)
Former smoker 103,536 (30.4) 48,552 (28.6) 54,984 (32.3)
Unknown 18,360 (5.4) 10,557 (6.2) 7803 (4.6)
BMI (kg/m2)
15–19 10,581 (3.1) 5976 (3.5) 4605 (2.7)
20–24 86,326 (25.4) 47,714 (28.1) 38,612 (22.7)
25–29 117,293 (34.5) 57,113 (33.6) 60,180 (35.4)
≥ 30 78,335 (23.0) 31,460 (18.5) 46,875 (27.5)
Unknown 47,682 (14.0) 27,729 (16.3) 19,953 (11.7)
PCP visitsc
0–1 11,729 (3.4) 5842 (3.4) 5887 (3.4)
2–4 43,481 (12.8) 21,711 (12.8) 21,770 (12.8)
5–9 98,550 (29.0) 49,238 (29.0) 49,312 (29.0)
10–19 130,757 (38.4) 65,353 (38.4) 65,404 (38.4)
≥ 20 55,700 (16.4) 27,848 (16.4) 27,852 (16.4)
BMI body mass index, COPD chronic obstructive pulmonary disorder, GI gastrointestinal, IBD inflammatory bowel disease
aThe number of individuals in each of the two cohorts is slightly lower than the 170,336 originally identified because later information from a more recent version
of the database showed that these patients had dropped out of the cohort (information that was not available in earlier versions of the database)
bAll variables were measured any time before the start of follow-up except for PCP visits, which were collected in the year before the start of follow-up
cIn the year before the start of follow-up (each new users of low-dose aspirin/non-exposed pair from the two cohorts was matched by number of PCP visits at the
start of follow-up, in addition to matching by sex and age at start of follow-up)
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irrespective of whether CRC stage was recorded or not
recorded; see Additional file 9), current users of low-
dose aspirin had an RR of 0.82 (95% CI: 0.74–0.92) with
the risk estimate lower with more than 5 years’ treat-
ment duration, RR: 0.72 (95% CI: 0.58–0.89).
Discussion
Patients starting treatment with low-dose aspirin had a
significant 34% decreased risk of developing CRC com-
pared with those not taking low-dose aspirin, in line
with previous findings of a chemopreventive effect of as-
pirin against CRC [2, 4, 18, 19]. The reduction in risk
was apparent across all age groups, and was unrelated to
dose, indication, gender, CRC location or case-fatality
status. We also found an effect of low-dose aspirin
among patients who started therapy after having previ-
ously undergone colonoscopy/sigmoidoscopy. The pro-
tective effect was observed in Dukes Stages B to D CRC,
occurring throughout treatment duration and starting
within the first year of therapy, while a suggestion of a
reduced risk of Dukes Stage A CRC was observed but
only after 5 years’ therapy.
To our knowledge, our study is the first to investigate
the effect of low-dose aspirin on risk of CRC by stage at
diagnosis among real-world patients in clinical practice.
A key strength of our study is the original observational
study design, which attempted to minimize bias between
aspirin users and non-users at start of follow-up that are
difficult to control. By obtaining incident cases of CRC
for our case–control analysis from two cohorts of pa-
tients – new users of low-dose aspirin and non-users of
low-dose aspirin at start of follow-up – matched by fac-
tors including a proxy for general health status, we
attempted to control for this possible selection bias. This
would not have been achieved from a traditional nested
Table 2 Frequency distribution of comorbidities, lifestyle factors
and healthcare use of CRC cases and controls, and their









0–1 486 (4.9) 92 (3.0) 1.00 (−)
2–4 1094 (10.9) 261 (8.6) 1.37 (1.06–1.79)
5–9 2624 (26.2) 699 (23.0) 1.76 (1.38–2.25)
10–19 3715 (37.1) 1164 (38.4) 2.28 (1.79–2.91)
≥ 20 2081 (20.8) 817 (26.9) 3.07 (2.38–3.96)
Referralsb
0–1 4760 (47.6) 1182 (39.0) 1.00 (−)
2–4 2778 (27.8) 917 (30.2) 1.28 (1.16–1.43)
5–9 1716 (17.2) 612 (20.2) 1.35 (1.19–1.53)
≥ 10 746 (7.5) 322 (10.6) 1.57 (1.33–1.85)
Hospitalizationsb
None 8496 (85.0) 2424 (79.9) 1.00 (−)
1 930 (9.3) 375 (12.4) 1.32 (1.16–1.51)
2 328 (3.3) 148 (4.9) 1.45 (1.18–1.77)
≥ 3 246 (2.5) 86 (2.8) 1.08 (0.83–1.39)
BMI (kg/m2)c
< 20 343 (3.4) 111 (3.7) 1.07 (0.85–1.35)
20–24 2665 (26.7) 774 (25.5) 1.00 (−)
25–29 3793 (37.9) 1144 (37.7) 1.03 (0.93–1.15)
≥ 30 2324 (23.2) 714 (23.5) 1.04 (0.92–1.17)
Unknown 875 (8.8) 290 (9.6) 1.25 (1.06–1.47)
Smoking status
Non-smoker 4378 (43.8) 1231 (40.6) 1.00 (−)
Current 1292 (12.9) 376 (12.4) 1.07 (0.94–1.23)
Former 4102 (41.0) 1362 (44.9) 1.20 (1.09–1.31)
Unknown 228 (2.3) 64 (2.1) 0.93 (0.69–1.27)
Alcohol consumption (units/week)d
None 1771 (17.7) 483 (15.9) 1.00 (−)
1–9 4722 (47.2) 1401 (46.2) 1.12 (0.99–1.26)
10–20 1521 (15.2) 480 (15.8) 1.21 (1.04–1.41)
≥ 21 725 (7.3) 274 (9.0) 1.46 (1.20–1.78)
Unknown 1261 (12.6) 395 (13.0) 1.15 (0.97–1.36)
Comorbiditiese
Diabetes 1852 (18.5) 598 (19.7) 0.98 (0.87–1.10)
IBD 124 (1.2) 40 (1.3) 1.04 (0.72–1.50)
IBS 534 (5.3) 176 (5.8) 1.02 (0.85–1.22)
Table 2 Frequency distribution of comorbidities, lifestyle factors
and healthcare use of CRC cases and controls, and their
association with risk of CRC (Continued)
Gout 765 (7.6) 250 (8.2) 1.10 (0.94–1.29)
Hypertension 5626 (56.3) 1740 (57.4) 1.01 (0.93–1.11)
Hypercholesterolemia 1655 (16.6) 484 (16.0) 0.96 (0.83–1.35)
Upper GI disorders 2165 (21.6) 656 (21.6) 0.93 (0.84–1.03)
BMI body mass index, CI confidence interval, CRC colorectal cancer, GI
gastrointestinal, IBD inflammatory bowel disease, IBS irritable bowel syndrome,
NSAIDS non-steroidal anti-inflammatory drugs, PCP primary care practitioner,
RR rate ratio, u/w units per week
aAdjusted by the matching variables (age, sex and year of index date) and
number of PCP visits, smoking (any time before index date), insulin, NSAIDs,
BMI (any time before index date) and oral steroids
bIn the year before the index date
cAny time before the index date taking the value recorded nearest to the
index date
dUnits per week = 10 ml (8 g) of pure ethanol
eAny time before the index date except for GI disorders, which were
ascertained anytime up to and including the start date. Reference group for all
comorbidities was not having the respective condition
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case–control study design in the whole THIN source
population, following up the single cohort to identify
cases of CRC. By then analyzing low-dose aspirin in our
case-control analysis in relation to the index date (i.e.
current use, never use etc), we evaluated actual use of
low-dose aspirin (assuming the patient took the medica-
tion) rather than use of low-dose aspirin defined at start
of follow-up, which could have changed substantially
over time. Other study strengths include the representa-
tiveness of the data source to the UK population, the
long study period, and the inclusion of a broad range of
patients, including those with gastrointestinal disorders.
Lag-time and stratified analyses showed the associations
to be robust and to occur across patient groups. All inci-
dent CRC cases were identified following thorough re-
view of EMRs, previous validation of the CRC diagnosis
of nearly 20% of our cases using record linkage to
hospitalization data, and through PCP questionnaires for
a smaller sample, resulting in high confirmation rates
[13]. Any potential differential misclassification of CRC
cases between low-dose aspirin users and non-users, for
instance diagnostic bias arising from more frequent in-
vestigation and referral of aspirin users, would have
underestimated the associations found. Although infor-
mation on Dukes Stage was unavailable for 53% of cases,
the distribution of Dukes Stage in cases with a recorded
stage is largely consistent with national data [20, 21]
supporting their representativeness to cases in the gen-
eral population. Furthermore, 1- and 5-year survival
rates for all cases are consistent with national rates [22].
Through sensitivity analysis restricted to CRC cases with
known stage, we showed the associations to be robust.
Misclassification of aspirin exposure owing to unre-
corded OTC aspirin in THIN was likely to have been
minimal, as shown in our previous validation study of
low-dose aspirin recording in THIN [16] and other pop-
ulations [23]. It is unlikely that our findings can be ex-
plained by healthy-user bias because we found the new
users of low-dose aspirin cohort to be less healthy in
terms of comorbidities and lifestyle factors than the
matched (at start of follow-up) cohort. In fact, any re-
sidual lack of adjustment for the more severe co-
morbidity profile of new low-dose aspirin users would
have led to an underestimation of the protective effect
seen. Furthermore, in another study using a similar de-
sign but where the non-user at start of follow-up cohort
instead comprised new users of a ‘neutral’ drug – para-
cetamol – we report highly similar results [24]. Also,
in this current study, we matched our two study cohorts
by number of PCP visits as a proxy for general health/
comorbidity. We controlled for several confounders in
our analyses, and the level of missing data for smoking
Table 3 Frequency distribution of low-dose aspirin among CRC cases and controls, and RR (95% CI) for their association with risk of CRC






RR (95% CI)a RR (95% CI)b
Recency
Non-use 3557 (35.6) 1247 (41.1) 1.00 (−) 1.00 (−)
Current use 4562 (45.6) 1255 (41.4) 0.80 (0.73–0.88) 0.66 (0.60–0.73)
Recent/past usec 475 (4.8) 158 (5.2) 0.73 (0.64–0.84) 0.78 (0.64–0.95)
Daily dosed
75 mg 4128 (41.3) 1137 (37.5) 0.78 (0.71–0.86) 0.66 (0.60–0.73)
150 mg 402 (4.0) 107 (3.5) 0.75 (0.60–0.94) 0.62 (0.50–0.78)
300 mg 32 (0.3) 11 (0.4) 0.97 (0.49–1.94) 0.82 (0.41–1.64)
Formulation
Plain 3716 (37.2) 1008 (33.2) 0.77 (0.70–0.85) 0.65 (0.59–0.72)
Enteric coated 846 (8.5) 247 (8.1) 0.83 (0.71–0.97) 0.70 (0.59–0.82)
Duration of use
< 1 year 1430 (14.3) 433 (14.3) 0.86 (0.76–0.97) 0.72 (0.63–0.82)
1–5 years 2370 (23.7) 632 (20.8) 0.76 (0.68–0.84) 0.64 (0.57–0.72)
≥ 5 years 762 (7.6) 190 (6.3) 0.70 (0.59–0.84) 0.61 (0.51–0.73)
All estimates are among current users of low-dose aspirin (reference group = non-use) unless otherwise specified
BMI body mass index, CI confidence interval, NSAIDS non-steroidal anti-inflammatory drugs, PCP primary care practitioner, RR rate ratio
aAdjusted by the matching factors (age, sex and year of index date)
bAdjusted by the matching factors (age, sex and year of index date) and number of PCP visits, smoking (any time before index date), insulin, NSAIDs,
BMI (any time before index date) and oral steroids
cFor patients with a duration of use of at least 1 year (25% of all recent/past users)
dRefers to the estimated average quantity dose. No appreciable difference in the results were observed when dose of the first prescription during follow-up
was used or when the dose of last prescription before the index date was used
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and body mass index was low with risk estimates virtu-
ally similar when these variables were ascertained before
the start of follow-up (data not presented). Although
data on certain CRC risk factors such as red meat intake
and a positive family history and were not recorded;
these are unlikely to be related to aspirin exposure and
confound the associations observed. Residual confound-
ing, however, cannot be ruled out. In addition, because
the mean length of low-dose aspirin use was 6 years, we
were unable to investigate the effect of low-dose aspirin
when used in the longer-term.
Our findings support an effect of low-dose aspirin on
at least two phases of the natural history of CRC. The
early and large reduction in risk seen among patients
presenting with Dukes Stage D CRC is consistent with
previous clinical trial data [4]. Experimental evidence ex-
ists to suggest that platelets play an important role in
metastasis [25, 26]. Pharmacological inhibition of
thromboxane synthase in animal models has been shown
to significantly inhibit tumour cell growth, invasion, me-
tastasis and angiogenesis [27]. The short-term effect of
aspirin on advanced stage CRC seen in our study sup-
ports the hypothesis that aspirin has an effect on the
progression of established tumours – a clinically import-
ant finding because of the poor prognosis of patients
presenting with advanced stage disease. Five-year sur-
vival for Dukes Stage D CRC cases in our study was 9%,
in line with previous reports [20]. At least 5 years’ ther-
apy with low-dose aspirin was necessary to observe a re-
duction in risk of Dukes A CRC, a latency period
consistent with the average time for an early stage car-
cinoma to evolve from an adenomatous polyp [28]. This
adds supports for an effect of aspirin early in the aden-
oma–carcinoma sequence [3]. Biologically plausible
mechanisms that could mediate an effect of aspirin
against CRC development have been postulated, also
Fig. 2 RRs (95% CIs) for the association between current use of low-dose aspirin and risk of CRC by case subgroup and subpopulation. RRs were
adjusted for the matching variables (age, sex and year of index date) and number of PCP visits, smoking (any time before index date), insulin,
NSAIDs, BMI (any time before index date) and oral steroids.. For all RRs other than those for each Dukes stage, all CRC cases were used irrespective of
whether stage was recorded or not recorded (unknown). *Deaths within the first year after CRC diagnosis were considered to be fatal cases. †Record of
an adenoma, colonoscopy or sigmoidoscopy. BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; GI, gastrointestinal, NSAIDS,
non-steroidal anti-inflammatory drugs; PCP, primary care practitioner; RR, rate ratio
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involving platelet inhibition [29]. Co-incubation of acti-
vated human platelets with CRC cells has been shown
to upregulate cyclooxygenase-2 (COX-2) expression
and induce epithelial-mesenchymal transition [30]. In-
duction of COX-2 expression in adjacent nucleated
cells could thereby trigger a chain of downstream
events affecting cell proliferation, apoptosis and angio-
genesis. At low-doses (75–100 mg daily), aspirin per-
manently inactivates the enzyme cyclooxygenase 1 in
platelets, leading to long-lasting suppression of thromb-
oxane A2 production.
For Dukes Stages B to D CRC, we did not observe the
latency period for an effect of low-dose aspirin as seen
in post-hoc analyses of trial data [2, 18]. And interest-
ingly, in a recent analysis of data from the Women’s
Health Initiative [31] use of statins – medication also re-
ported as having anti-cancer properties [32] – was found
to be associated with a significant reduction in CRC
mortality. There are several possible reasons why we
were able to identify cases earlier during follow-up than
previous aspirin trials. Firstly, our study was designed to
investigate CRC as the clinical endpoint, and informa-
tion on low-dose aspirin use throughout the whole
follow-up was ascertained and analyzed. Secondly, our
study did not screen-out patients with peptic ulcer disor-
ders or other disease-related eligibility criteria, and some
of these patients may have had preclinical CRC, already
along the lengthy adenoma–carcinoma sequence at start
of follow-up. Thirdly, our study population included
real-world patients, which included those with multiple
comorbidities; the average age of patients at start of
follow-up was 64 years in our study compared with 61
in four previous low-dose aspirin trials [2]. Fourthly,
follow-up began between 2000 and 2009, considerably
later than the start of several trials that began in early/
mid 1980s. Irrespective of the age and health of the
study population, there have been temporal changes in
the management of CRC, including the availability of
better diagnostic techniques, the introduction of multi-
disciplinary teams in secondary care, the national bowel
cancer screening programme, bowel cancer awareness
initiatives/increased media attention, and accessibility to
information.
In line with trial data [2], we found an aspirin dose of
75 mg/day to be effective in reducing CRC. No in-
creased benefit was seen with up to four-fold higher as-
pirin doses, although our study was underpowered to
reliably evaluate these exposures with around 90% of
current low-dose aspirin use at 75 mg/day. Neverthe-
less, this is an important finding considering that doses
of less than 100 mg are sufficient to reduce the risk of
thrombotic cardiovascular events, and the dose-
dependent increased risk of gastrointestinal bleeding
[33]. The benefits of low-dose aspirin in reducing
ischaemic vascular events [34] must be weighed against
the risk of gastrointestinal bleeding, which increases
with age and when aspirin is prescribed alongside other
gastrotoxic agents [33]. Prevention strategies to
minimize aspirin-associated gastrointestinal problems,
such as use of proton pump inhibitors, have conferred
an acceptable safety profile for low-dose aspirin use in
the general population and thereby the potential for use
in CRC prophylaxis. Recently, the U.S. Preventive
Services Task Force issued a draft recommendation
statement advocating long-term use of low-dose aspirin
for primary prevention of CRC and CVD among adults
aged 50 to 59 years who have a 10% or greater 10-year
CVD risk and who are not at increased risk of bleeding
[35]. For comparable adults aged 60 to 69 years, the
Task Force recommends the decision to take low-dose
aspirin for primary CRC and CVD prevention should
be made on an individual basis. A quantification of the
gastrointestinal safety profile of low-dose aspirin in our
patient population is warranted to make a valid benefit/
risk evaluation in CRC prevention. There is also a need
for our results for CRC stage to be verified in other
large, population-based, observational studies. The
potential for low-dose aspirin to be used post-diagnosis
as adjuvant treatment to prevent recurrence and
prolong survival is another promising research question
and is currently being assessed in the ongoing placebo-
controlled ADD-Aspirin trial [36].
Conclusions
Our results indicate that patients starting low-dose as-
pirin therapy have a reduced risk of Stages B–D CRC
suggesting a role for low-dose aspirin in the progression
of established CRC. When used in the long-term (5 years
or more), low-dose aspirin may also substantially reduce
the risk of Dukes A CRC.
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